DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20220673
Published: 2022-02-28

Retracted: Effect of dolutegravir on plasma glucose among human immunodeficiency virus patients in a community health center setting

Foud O Bahamdain

Abstract


The article "Effect of dolutegravir on plasma glucose among human immunodeficiency virus patients in a community health center setting" is retracted by the Editor-in-Chief. The article is retracted as per the corresponding author’s request.


Keywords


HIV, Dolutegravir, Diabetes

Full Text:

PDF

References


Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics‐2017 update: a report from the American Heart Association. Circulation. 2017;135(10):146-603.

Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179-84.

Dow DE, Bartlett JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Ther. 2014;3(2):83-102.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade V, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700-8.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-18.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-43.

Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;3(1):354-62.

McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73(1):258-60.

Fong PS, Flynn DM, Evans CD, Korthuis PT. Integrase strand transfer inhibitor-associated diabetes mellitus: a case report. Int J STD AIDS. 2017;28(6):626-8.

Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003;52(7):1695-700.

Rimawi BH, Johnson E, Rajakumar A, Tao S, Jiang Y, Gillespie, et al. Pharmacokinetics and placental transfer of elvitegravir, dolutegravir, and other antiretrovirals during pregnancy. Antimicrob Agents Chemother. 2017;61(6):2213-6.

Hernandez-Romieu, Alfonso C. Current neurology and neuroscience reports. U. S. Natnl Libr Med. 2017.

Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014;5(4):164-77.

Micromedex Solutions. Dolutegravir Sodium. Available at: http://www.micromedexsolutions.com. Accessed on 15 January 2022.

Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA. 2000;284(10):1263-70.

Usitalo A, Leister E, Tassiopoulos K, Allison S, Malee K, Paul M, et al. Relationship between viral load and behavioral measures of adherence to antiretroviral therapy in children living with HIV in Latin America. Braz J Infect Dis. 2015;19(3):263-71.

John DP, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Am Diabet Assoc. 200;29(3):725-31.